BGMS Bio Green Med Solution, Inc.
Mergers ·
Net loss was $0.4 million for the quarter ended June 30, 2026, while the company advances a share exchange that would make Future NRG Sdn. Bhd. a wholly owned subsidiary.
The sale at $0.72 per share closed on June 10, 2026 under Regulation S, and the filing names no underwriter, placement agent or financial advisor.
A Business Combination Agreement would make Future NRG Sdn. Bhd., a Malaysian medical waste treatment company, a wholly owned subsidiary of Bio Green Med Solution, with closing expected in the fourth quarter of 2026.
The 6% Convertible Exchangeable Preferred Stock, under the symbol BGMSP, stopped trading in March. The common stock, BGMS, remains listed, and first-quarter product revenue was $0.8 million.
Nasdaq says the 6% Convertible Exchangeable Preferred Stock has been below the $1 million minimum for publicly held shares for 30 consecutive business days. The company has until March 10, 2026 to regain compliance, and its 8-K does not say how it will get there.
Cyclacel Pharmaceuticals, now Bio Green Med Solution, agreed to exchange Series C warrants for 559,395 new common shares. The 8-K gives no exercise price and describes no cash payment.
Cyclacel filed the notice on March 31, 2025, saying it needed more time to gather information. It expects to file within fifteen calendar days.
Investor David Lazar agreed to subscribe for $3.1 million of convertible preferred stock and become interim chief executive. A separate warrant exchange would issue 24,844,725 common shares and pay $1,100,000 in cash. The Series D closing and the warrant exchange need stockholder approval, and the Nasdaq deadline is February 6, 2025.
Bio Green Med Solution, Inc., formerly Cyclacel Pharmaceuticals, Inc., now specializes in the supply and trading of protective and fire safety equipment, with a focus on Malaysia's fire safety market and on commercial, industrial, healthcare and residential customers. The company says it has more than 30 years of experience in fire safety. The change followed several transactions. Its clinical research programs had been conducted through Cyclacel Limited, a subsidiary that entered creditors' voluntary liquidation, announced in the London Gazette on January 31, 2025. The company sold its patent rights for plogosertib (Plogo) to Tethra Biosciences Inc. for $300,000, plus a potential milestone payment of $170,000. The company closed a share exchange with FITTERS Diversified Berhad on September 12, 2025, under which Fitters Sdn. Bhd., a Malaysia-based company, became a wholly owned subsidiary. Product categories include fire extinguishers, foam systems, fire-resistant doors, personal protective equipment and fire safety apparel. The text says its products are approved by BOMBA and certified by SIRIM.
| Product or program | What it is | Stage |
|---|---|---|
| Fire extinguishers and foam systems | Fire-fighting equipment, including the FITTERS FIRE-X extinguisher and foam systems | Distributed; approved by BOMBA and certified by SIRIM |
| Fire-resistant doors | Fire-resistant doors supplied to customers | Offered as a product category |
| Personal protective equipment and fire safety apparel | Protective equipment and safety apparel for fire safety | Offered as a product category |
| Line | FY2025 | FY2024 |
|---|---|---|
| Revenue | $0 | $43,000 |
| Research and development | $848,000 | $6.7 million |
| Net income (loss) | -$3.0 million | -$11.2 million |
| Cash from operations | -$4.8 million | -$8.0 million |
| Cash and equivalents | $3.5 million | $3.1 million |
Our latest story on this, dated May 14, 2026: "Preferred stock removed from Nasdaq as Bio Green Med reports first-quarter results". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Jun 4, 2026: "Bio Green Med agrees to all-stock deal to acquire Future NRG". The story links the filing or release it is based on. Read the story.
Bio Green Med Solution, Inc. trades under the ticker BGMS on NASDAQ.
Bio Green Med Solution, Inc. is listed on NASDAQ. Our directory also records these other listings: OTC:BGMSP.
The SEC Central Index Key (CIK) for Bio Green Med Solution, Inc. is 1130166. Its filings are on SEC EDGAR.
6,622,794 shares as of 2026-08-11, per the cover page of its 10-Q filed 2026-08-14.
Our directory records Bio Green Med Solution, Inc. under Malaysia.
Our directory classifies Bio Green Med Solution, Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.
The ISIN recorded for Bio Green Med Solution, Inc. is US23254L8761.
aibio.space lists Bio Green Med Solution, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as DE.
Bio Green Med Solution, Inc., formerly Cyclacel Pharmaceuticals, Inc., now specializes in the supply and trading of protective and fire safety equipment, with a focus on Malaysia's fire safety market and on commercial, industrial, healthcare and residential customers. The company says it has more than 30 years of experience in fire safety.
Fire extinguishers and foam systems: Fire-fighting equipment, including the FITTERS FIRE-X extinguisher and foam systems Stage: Distributed; approved by BOMBA and certified by SIRIM.
Fire-resistant doors: Fire-resistant doors supplied to customers Stage: Offered as a product category.
$0 for the fiscal year ended Dec 31, 2025, as reported to the SEC.
Reported a merger or acquisition agreement. SEC Form 8-K (Items 1.01,7.01,9.01). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 2.02,7.01,9.01). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). Source
Reported a reverse stock split. SEC Form 8-K (Items 2.02,7.01,9.01). Source
Reported a financing. SEC Form 8-K (Items 1.01,3.02,9.01). Source
Reported completing an acquisition or a sale of assets. SEC Form 8-K (Items 1.01,2.01,9.01). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). Source
Reported completing an acquisition or a sale of assets. SEC Form 8-K (Items 2.01,3.03,5.03,7.01,9.01). Source
Reported a financing. SEC Form 8-K (Items 1.01,3.02,9.01). Source
Reported a change of independent auditor. SEC Form 8-K (Items 4.01,9.01). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 2.02,7.01,9.01). Source
Filed documents for a merger or acquisition. SEC Form 425. Source
Reported a reverse stock split. SEC Form 8-K (Items 5.03,7.01,9.01). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01,9.01). Source
Reported a reverse stock split. SEC Form 8-K (Items 5.03,7.01,9.01). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 2.02,5.02,7.01,9.01). Source
Told the SEC a periodic report would be filed late. SEC Form NT 10-K. Source
Reported completing an acquisition or a sale of assets. SEC Form 8-K (Items 1.01,2.01,9.01). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 1.01,3.01,3.03,5.01,5.02,9.01). Source
Reported a financing. SEC Form 8-K (Items 1.01,9.01). Source
Reported a financing. SEC Form 8-K (Items 1.01,3.02,5.07,8.01,9.01). Source
Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. Source
Reported a financing. SEC Form 8-K (Items 1.01,9.01). Source
Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. Source
Reported a merger or acquisition agreement. SEC Form 8-K (Items 1.01,3.02,3.03,5.02,5.03,8.01,9.01). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). Source
Reported a change of independent auditor. SEC Form 8-K (Items 4.01,9.01). Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio